Last verified: April 2026

The June 2024 Investigation — St. John & Halperin

In June 2024, Los Angeles Times investigative reporters Paige St. John and Alex Halperin published the results of an investigation that would reshape the conversation about cannabis product safety in regulated markets. The reporters purchased 42 cannabis products from licensed California dispensaries — products that had all passed mandatory state-regulated testing — and submitted them for independent laboratory analysis using methods capable of detecting a wider range of contaminants than California’s required testing panel.

The results were damning. Of the 42 legally sold products:

• 25 products (60%) exceeded contamination limits for one or more toxic chemicals
• A total of 45 distinct toxic chemicals were detected across the sample set
• Many of the detected contaminants were not on California’s 66-compound required testing panel, meaning they could not have been caught by the mandated testing process regardless of laboratory competence

The investigation focused particular attention on pymetrozine, an insecticide that is not included in California’s 66-compound testing panel. Among products from a single brand, 13 of 14 tested products contained pymetrozine at concentrations reaching 60 times the federal tolerance level for food crops. Because pymetrozine is not on the state’s testing panel, these products passed every required laboratory test.

California’s testing program for legal marijuana fails to screen for the majority of pesticides known to be used on cannabis, leaving consumers exposed to potentially hazardous chemicals.

Paige St. John and Alex Halperin, Los Angeles Times, June 2024

The 66-Compound Gap — What California Doesn’t Test For

California’s cannabis testing regulations require laboratories to screen for 66 specific pesticide compounds. This number appears comprehensive until compared to the hundreds of pesticides, fungicides, growth regulators, and other agricultural chemicals potentially used in cannabis cultivation. The testing panel was established when California’s regulated market launched and has not been substantially updated since, even as cultivators have adapted their chemical usage to avoid the specific compounds on the panel.

The regulatory gap is structural: cultivators know exactly which 66 compounds will be tested and can select chemicals that are not on the list. This is not hypothetical — the pymetrozine finding demonstrates it directly. A cultivator using pymetrozine (which is effective against whiteflies and aphids, common cannabis pests) faces zero regulatory risk because the compound will never appear on a Certificate of Analysis, regardless of its concentration in the product.

The parallel to drug testing in sports is instructive. Anti-doping agencies discovered decades ago that a fixed panel of banned substances simply drives athletes to novel compounds not yet on the list. Effective testing requires continuous panel expansion, intelligence-driven targeting of emerging chemicals, and broad-spectrum screening capable of detecting unknown contaminants. California’s cannabis testing system has none of these capabilities.

The December 2024 Follow-Up — More Than Half Unmonitored

In December 2024, the Los Angeles Times published follow-up reporting with additional testing data that deepened the original findings. The updated analysis revealed that more than 50% of the chemical contaminants detected in legal California cannabis products were compounds not included on the state’s required testing panel.

This finding reframes the contamination problem. The original investigation might have been interpreted as a failure of laboratory execution — labs not catching what they should catch. The follow-up demonstrates that even if every laboratory in California performed flawlessly on every required test, the majority of the contamination problem would remain invisible. The gap is in the regulatory design, not (only) in laboratory competence.

The December reporting also documented the political dynamics that have prevented panel expansion. Cannabis testing laboratories, cultivators, and manufacturers have resisted expanded panels because they increase testing costs, increase the probability of failing results (destroying inventory), and slow time-to-market. Regulators have been reluctant to impose costs on an industry already struggling with tax burden and illicit market competition.

Why Cannabis Contaminants Matter — The Inhalation Route

The public health significance of cannabis contamination is amplified by the route of administration. The majority of cannabis consumption in the United States involves inhalation — smoking or vaporization — which delivers contaminants directly to pulmonary alveolar surfaces and into systemic circulation without first-pass hepatic metabolism. Pesticide tolerance levels established by the EPA for food crops assume oral ingestion, hepatic processing, and gastrointestinal barriers that do not apply when the same chemicals are inhaled.

When pesticides undergo pyrolysis (thermal decomposition at combustion temperatures), they can produce degradation products more toxic than the parent compound. Myclobutanil decomposes to hydrogen cyanide. Chlorpyrifos produces chlorpyrifos oxon, a potent cholinesterase inhibitor. Bifenthrin can generate aldehydes and other reactive intermediates. The toxicology of pyrolytic pesticide degradation products in cannabis smoke has received almost no systematic study.

For immunocompromised patients — cancer patients on chemotherapy, organ transplant recipients on immunosuppressants, HIV/AIDS patients with depleted CD4 counts — microbial contaminants (particularly Aspergillus species) represent an acute life-threatening hazard. Invasive pulmonary aspergillosis from cannabis inhalation has been documented in case reports and carries mortality rates exceeding 50% in severely immunosuppressed populations. These patients represent the population most likely to use medical cannabis (for chemotherapy-induced nausea, pain, and appetite stimulation) and most vulnerable to its microbial contaminants.

What Reforms Would Look Like

The investigations point toward specific, actionable reforms that have been resisted on cost and political grounds but are technically straightforward:

• Blind testing protocols — samples submitted through a regulatory intermediary so laboratories cannot identify the client, eliminating the financial incentive to inflate potency or overlook contaminants
• Independent reference laboratories — state-operated or state-contracted facilities conducting random retesting of products already on shelves, with public reporting of discrepancies
• AOAC/ASTM validated methods — mandatory adoption of collaboratively validated analytical methods developed by the Association of Official Analytical Collaboration (AOAC) and ASTM International, replacing each laboratory’s proprietary in-house methods
• Payment separation — cultivators pay testing fees into a pooled fund administered by the regulatory agency, which assigns samples to laboratories on a rotational basis, severing the direct financial relationship
• Dynamic testing panels — regular expansion of required analyte lists based on intelligence about chemicals actually being used, with broad-spectrum screening (e.g., untargeted LC-HRMS analysis) supplementing targeted compound lists
• Inhalation-specific tolerance levels — establishment of maximum residue levels specific to inhaled products, which should be substantially lower than oral tolerance levels given the absence of first-pass metabolism and hepatic detoxification

Oregon’s ORELAP (Oregon Environmental Laboratory Accreditation Program) and Canada’s Health Canada analytical requirements represent incrementally better models, though no jurisdiction has fully implemented the reforms outlined above. The cannabis industry’s testing infrastructure remains, in comparative terms, decades behind pharmaceutical, food, and environmental testing standards.

What Consumers Can Do Now

Until structural reforms are implemented, consumers face a testing system that provides incomplete and potentially misleading assurances. Practical steps include:

• Verify the laboratory — check whether the lab on the COA still holds an active license and whether it has been subject to enforcement actions (California’s DCC maintains a public license database)
• Be skeptical of extreme THC claims — flower consistently labeled above 30% THC should be viewed with particular suspicion given the documented inflation patterns
• Consider the route — edibles pose lower contaminant risk than inhaled products because hepatic first-pass metabolism provides a partial detoxification buffer
• Favor established brands with track records — brands that have operated for years without enforcement actions are at least surviving regulatory scrutiny, though this is a weak signal
• Recognize the limits of COAs — a passing result means the product passed the tests that were performed; it does not mean the product is free of all contaminants